ALLERGY THERAPEUTICS PLC — Director's Dealing 2015

Jul 27, 2015

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 0973U

Allergy Therapeutics PLC

27 July 2015

27 July 2015

Allergy Therapeutics plc

Director Share Dealings

On 24 July 2015, the Board of Allergy Therapeutics plc ("Allergy Therapeutics" or "the Company") was informed that on 24 July 2015, Manuel Llobet, Chief Executive Officer, purchased 50,000 ordinary shares of 0.10p ("Ordinary Shares") at a price of 24.45p per share.  Mr Llobet's beneficial holding now stands at 3,175,000 Ordinary Shares, which represents 0.58% of the issued share capital of the Company to which voting rights are attached.

- Ends -

For further information:

Allergy Therapeutics	+44 (0) 1903 845 820
Ian Postlethwaite, Finance Director
Panmure Gordon	+44 (0) 20 7886 2500
Freddy Crossley / Peter Steel / Duncan Monteith, Corporate Finance
Tom Salvesen, Corporate Broking
FTI Consulting	+44 (0) 20 3727 1000
Simon Conway / Victoria Foster Mitchell

Note to editors:

About Allergy Therapeutics

Allergy Therapeutics is a specialty pharmaceutical company focused on allergy vaccination.  It has a growing business achieving revenue in the last financial year of £42 million mainly in Europe through its own sales and marketing infrastructure and further afield through distributors.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSSEFEEMFISESW